Pharmacodynamics: Relation to antimicrobial resistance

American Journal of Infection Control

Volumn 34, Issue 5 SUPPL., 2006, Pages

  Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; GLYCOPEPTIDE; KETOLIDE; LEVOFLOXACIN; MACROLIDE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL;

EID: 33745235120     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2006.05.227     Document Type: Article

References (43)

1. Nicolau D.P. Antimicrobial therapy and emerging pathogens. Am J Manag Care 4 suppl 2 (1998) S525-S530
2. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2 (2004) 289-300
3. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55 (2005) 601-607
4. Estes L. Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin Proc 73 (1998) 1114-1122
5. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10 quiz 11-2
6. Lacy M.K., Nicolau D.P., Nightingale C.H., and Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 27 (1998) 23-27
7. Lode H., Borner K., and Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27 (1998) 33-39
8. Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis 27 (1998) 28-32
9. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis 27 (1998) 10-22
10. Vesga O, Bonnat C, Craig WA. In vivo pharmacodynamic activity of HMR 3647, a new ketolide [poster F255]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sept 28-Oct 1; Toronto, Ontario, Canada; 1997.
11. Lodise T.P., Preston S., Bhargava V., et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis 52 (2005) 45-52
12. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
13. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., and Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189 (2004) 1590-1597
14. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129
15. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., and Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45 (2001) 2793-2797
16. Craig W.A., and Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 15 (1996) 255-259
17. Dagan R., Leibovitz E., Greenberg D., Yagupsky P., Fliss D.M., and Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 17 (1998) 776-782
18. Dagan R, Piglansky L, Yagupsky P, Fliss DM, Leiberman A, Leibovitz E. Bacteriologic response in acute otitis media: comparison between azithromycin, cefaclor, and amoxicillin [abstract K-103]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sept 28-Oct 1; Toronto, Ontario, Canada; 1997.
19. Leibovitz E, Piglansky L, Raiz S, et al. The bacteriologic efficacy of 1-day versus 3-day intramuscular ceftriaxone in the treatment of non-responsive acute otitis media [abstract K-105]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sept 28-Oct 1; Toronto, Ontario, Canada; 1997.
20. Thomas J.K., Forrest A., Bhavnani S.M., et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 42 (1998) 521-527
21. Epstein B.J., Gums J.G., and Drlica K. The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother 38 (2004) 1675-1682
22. Dong Y., Zhao X., Domagala J., and Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999) 1756-1758
23. Dong Y., Zhao X., Kreiswirth B.N., and Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44 (2000) 2581-2584
24. Zhao X., and Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 185 (2002) 561-565
25. Grant F.M., and Nicolau D.P. Pharmacodynamic considerations in the selection of antibiotics for respiratory tract infections: focus on the fluoroquinolones. Antibiotics for Clinicians 3 suppl 1 (1999) 21-28
26. LaPlante K, Rybak M, Tsuji B, Kaatz GW. Resistance in Streptococcus pneumoniae: AUC/MIC breakpoints differ between gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin [abstract P-1019]. Presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 April 2-5; Copenhagen, Denmark; 2005.
27. Florea N.R., Tessier P.R., Zhang C., Nightingale C.H., and Nicolau D.P. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob Agents Chemother 48 (2004) 1215-1221
28. Croisier D., Chavanet P., Lequeu C., et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50 (2002) 349-360
29. Jumbe N., Louie A., Leary R., et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112 (2003) 275-285
30. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17 (2003) 479-501
31. Dudley M, Griffith D, Corcoran E, et al. Pharmacokinetic-pharmacodynamic indices for vancomycin treatment of susceptible and intermediate S. aureus in the neutropenic mouse thigh model [abstract 2031]. Presented at the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1999 Sept 26-29; San Francisco, CA; 1999.
32. Sakoulas G., Eliopoulos G.M., Moellering Jr. R.C., et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?. J Infect Dis 187 (2003) 929-938
33. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., and Moellering Jr. R.C. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38 (2004) 1700-1705
34. Ji G., Beavis R.C., and Novick R.P. Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc Natl Acad Sci U S A 92 (1995) 12055-12059
35. Arvidson S., and Tegmark K. Regulation of virulence determinants in Staphylococcus aureus. Int J Med Microbiol 291 (2001) 159-170
36. Recsei P., Kreiswirth B., O'Reilly M., Schlievert P., Gruss A., and Novick R.P. Regulation of exoprotein gene expression in Staphylococcus aureus by agar. Mol Gen Genet 202 (1986) 58-61
37. Novick R.P., Ross H.F., Projan S.J., Kornblum J., Kreiswirth B., and Moghazeh S. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. Embo J 12 (1993) 3967-3975
38. Jarraud S., Lyon G.J., Figueiredo A.M., et al. Exfoliatin-producing strains define a fourth agr specificity group in Staphylococcus aureus. J Bacteriol 182 (2000) 6517-6522
39. Yarwood J.M., Bartels D.J., Volper E.M., and Greenberg E.P. Quorum sensing in Staphylococcus aureus biofilms. J Bacteriol 186 (2004) 1838-1850
40. Yarwood J.M., and Schlievert P.M. Quorum sensing in Staphylococcus infections. J Clin Invest 112 (2003) 1620-1625
41. Tsuji B, Rybak M. The influence of Staphylococcus aureus accessory gene regulator function on the development of glycopeptide heteroresistance in an in vitro pharmacodynamic model [abstract P-1590]. Presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 April 2-5; Copenhagen, Denmark; 2005.
42. O'Brien R.J., and Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 26 (2005) 327-340 vii
43. Klibanov O.M., Raasch R.H., and Rublein J.C. Single versus combined antibiotic therapy for gram-negative infections. Ann Pharmacother 38 (2004) 332-337